HealthDay News — Many patients with overweight or obesity discontinue glucagon-like peptide-1 (GLP-1) receptor agonist therapy within one year, with higher discontinuation rates seen for those without ...
Glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications for weight loss are significantly transforming the fiel ...
News Medical on MSN1d
Diabetes drugs may boost brain health but experts warn of risksRAs, originally for diabetes, may impact brain health, finding potential benefits for dementia and addiction but inconsistent ...
Researchers had found in a new study that sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 ...
Scientists have discovered an antibody treatment that may help prevent both muscle loss and bone density loss in people using ...
ORLANDO, FLA. — Increasing levels of protein and fiber, stressing portion control and adding savory flavors are ways that ...
As the body of research expands on the potential of glucagon-like peptide-1 receptor agonists to address various health ...
UK: A recent consensus statement from leading UK medical organizations-including the Association of Anaesthetists,the ...
Sodium-glucose cotransporter 2, or SGLT2, inhibitors and glucagon-like peptide-1 receptor agonists lowered the risk for COPD ...
The use of glucagon-like peptide-1 receptor agonists is likely to increase the risks of inadequate bowel preparation for colonoscopy, according to a study published Feb. 12 in The American Journal of ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback